Skip to main content

Table 2 Between and within groups differences on the pulmonary function test, 6-min walking test (6MWT), and laboratory data at the baseline, at 4 weeks, and after 12 weeks (N = 44)

From: Effect of high-flow nasal therapy during early pulmonary rehabilitation in patients with severe AECOPD: a randomized controlled study

 

Non-HFNT PR

HFNT PR

Between-group test

Baseline (n = 22)

4 weeks (n = 22)

12 weeks (n = 22)

Baseline (n = 22)

4 weeks (n = 22)

12 week (n = 22)

4 weeks

12 weeks

p value

Pulmonary function test

 FVC, L

2.29 ± 0.76

2.38 ± 0.73**a

2.40 ± 0.74**a

2.26 ± 0.68

2.38 ± 0.69

2.42 ± 0.69

0.990

0.932

 FEV1, L

0.83 ± 0.24

0.84 ± 0.23

37.5 ± 39.6

0.86 ± 0.26

0.88 ± 0.26

0.92 ± 0.26**a,b

0.550

0.324

 FEV1/FVC, %

39.6 ± 12.8

39.6 ± 12.5

39.6 ± 12.5

40.2 ± 11.0

40.3 ± 11.2

40.4 ± 11.6

0.840

0.833

 Delta IC, L

−0.22 ± 0.18

−0.18 ± 0.16

−0.16 ± 0.15*a

−0.18 ± 0.17

−0.13 ± 0.12*a

−0.09 ± 0.13**a

0.146

0.099

6MWT

 6MWD, m

128.5 ± 85.6

191.4 ± 89.3

245.5 ± 103.1**a,b

178.9 ± 81.6

260.1 ± 87.7**a

304.6 ± 84.4**a,b

0.014c

0.044c

 SpO2, % pre 6MWT

94.4 ± 3.4

95.0 ± 3.1

95.5 ± 2.6*a

93.8 ± 2.5

95.1 ± 2.4*a

95.6 ± 2.1**a

0.957

0.802

 SpO2, % post 6MWT

87.4 ± 4.2

88.9 ± 4.9*a

90.5 ± 2.8**a,b

88.9 ± 4.4

90.7 ± 3.1**a

91.8 ± 2.4**a

0.136

0.103

 HR, pre 6MWT

98.4 ± 10.7

92.1 ± 11.3**a

91.7 ± 10.8**a

96.5 ± 11.5

92.6 ± 10.5**a

91.3 ± 10.4**a

0.880

0.899

 HR, post 6MWT

125.6 ± 8.1

124.4 ± 7.8

125.1 ± 7.4

125.6 ± 14.0

122.7 ± 6.4

122.0 ± 6.6

0.426

0.141

Laboratory data

 WBCs, 103/μl

14.80 ± 5.22

8.73 ± 2.01**a

7.92 ± 1.56**a

14.71 ± 4.44

8.18 ± 2.65**a

7.06 ± 1.51**a

0.439

0.072

 CRP, mg/dl

8.41 ± 6.77

1.73 ± 1.73**a

0.30 ± 0.39**a

5.11 ± 5.60

1.07 ± 1.57**a

0.07 ± 0.12**a

0.192

0.020c

 pH

7.36 ± 0.08

7.40 ± 0.04**a

7.42 ± 0.05**a

7.36 ± 0.08

7.41 ± 0.05*a

7.42 ± 0.04**a

0.479

0.949

 PaCO2, mmHg

51.5 ± 24.1

45.1 ± 15.5*a

45.1 ± 13.5*a

52.6 ± 20.3

40.1 ± 5.5*a

46.0 ± 17.0**a

0.752

0.755

 PaO2, mmHg

63.2 ± 15.3

82.9 ± 21.0**a

81.9 ± 18.0**a

66.1 ± 14.7

82.7 ± 16.8**a

83.1 ± 17.3**a

0.976

0.825

 HCO3−

24.88 ± 4.24

25.04 ± 5.82*a

27.35 ± 4.51*a,b

26.26 ± 5.98

27.15 ± 4.04

28.75 ± 4.15*a

0.169

0.290

  1. Values are the mean ± SD; Delta inspiratory capacity (IC), post-6MWT IC - pre-6MWT IC
  2. a Baseline vs. 4 weeks and 12 weeks; b 4 weeks vs. 12 weeks; * p < 0.05, ** p < 0.01; c delta, 12 weeks - baseline and 4 weeks - baseline
  3. Abbreviations: FEV1 forced expiratory volume in the first second; FVC forced vital capacity; 6MWD, 6-min walking distance; SpO2 oxyhemoglobin saturation by pulse oximetry; HR heart rate; IC inspiratory capacity; WBCs white blood cells; CRP C-reactive protein; PaCO2 partial pressure of carbon dioxide; PaO2 partial pressure of oxygen; HCO3− hydrogen carbonate bicarbonate ion